FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Takeda, 2010, Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity, J Clin Oncol, 28, e273, 10.1200/JCO.2009.26.5496 Ho, 2005, Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib, J Clin Oncol, 23, 8531, 10.1200/JCO.2004.00.6650 Shi, 2020, Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors, Expert Opin Drug Metab Toxicol, 16, 217, 10.1080/17425255.2020.1727886 Lee, 2016, Hepatotoxicity of targeted therapy for cancer, Expert Opin Drug Metab Toxicol, 12, 789, 10.1080/17425255.2016.1190831 Holt, 2006, Mechanisms of drug-induced liver injury, AAPS J, 8, E48, 10.1208/aapsj080106 Li, 2009, Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities, Chem Res Toxicol, 22, 1736, 10.1021/tx900256y Zhang, 2018, Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes, Toxicol Lett, 291, 138, 10.1016/j.toxlet.2018.04.010 McKillop, 2004, In vitro metabolism of gefitinib in human liver microsomes, Xenobiotica, 34, 983, 10.1080/02772240400015222 Liu, 2015, Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism, Biochem Pharmacol, 97, 111, 10.1016/j.bcp.2015.07.010 Kawamura, 2020, Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity, Cancer Chemother Pharmacol, 85, 605, 10.1007/s00280-020-04034-y Xin, 2015, The dissociation of gefitinib trough concentration and clinical outcome in NSCLC patients with EGFR sensitive mutations, Sci Rep, 5, 12675, 10.1038/srep12675 Kobayashi, 2016, Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib, Med Oncol, 33, 57, 10.1007/s12032-016-0773-5 Takimoto, 2013, Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity, Clin Lung Cancer, 14, 502, 10.1016/j.cllc.2013.03.003 Sugiyama, 2015, Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations, Lung Cancer, 90, 307, 10.1016/j.lungcan.2015.08.004 Wang, 2016, Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer, Anti Cancer Drugs, 27, 245, 10.1097/CAD.0000000000000323 2009 Hu, 2013, Human fetal hepatocyte line, L-02, exhibits good liver function in vitro and in an acute liver failure model, Transplant Proc, 45, 695, 10.1016/j.transproceed.2012.09.121 Luo, 2021, PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1), Autophagy, 17, 3221, 10.1080/15548627.2020.1851492 Ahmed, 2011, Aldo-keto reductase-7A protects liver cells and tissues from acetaminophen-induced oxidative stress and hepatotoxicity, Hepatology, 54, 1322, 10.1002/hep.24493 McKillop, 2004, Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man, Xenobiotica, 34, 917, 10.1080/00498250400009171 Guan, 2019, Development and validation of a sensitive LC–MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients, J Pharm Biomed Anal, 172, 364, 10.1016/j.jpba.2019.03.060 Xin, 2020, Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients, Pharmacogenomics J, 20, 285, 10.1038/s41397-019-0115-z Kijima, 2011, Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism, J Clin Oncol, 29, e588, 10.1200/JCO.2010.34.3368 Kobayashi, 2015, Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer, Clin Lung Cancer, 16, 274, 10.1016/j.cllc.2014.12.004 Ma, 2017, Determinants of gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters, Pharmacogenomics J, 17, 325, 10.1038/tpj.2016.31 Seki, 2006, Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration, J Clin Oncol, 24, 3213, 10.1200/JCO.2006.05.7109 Wandrer, 2020, Autophagy alleviates amiodarone-induced hepatotoxicity, Arch Toxicol, 94, 3527, 10.1007/s00204-020-02837-9 Wang, 2019, Farrerol ameliorates APAP-induced hepatotoxicity via activation of Nrf2 and autophagy, Int J Biol Sci, 15, 788, 10.7150/ijbs.30677 Zheng, 2019, Emodin-induced autophagy against cell apoptosis through the PI3K/AKT/mTOR pathway in human hepatocytes, Drug Des Devel Ther, 13, 3171, 10.2147/DDDT.S204958 Ni, 2012, Activation of autophagy protects against acetaminophen-induced hepatotoxicity, Hepatology, 55, 222, 10.1002/hep.24690 Ni, 2016, Removal of acetaminophen protein adducts by autophagy protects against acetaminophen-induced liver injury in mice, J Hepatol, 65, 354, 10.1016/j.jhep.2016.04.025 Chen, 2016, Autophagy is essential for ultrafine particle-induced inflammation and mucus hyperproduction in airway epithelium, Autophagy, 12, 297, 10.1080/15548627.2015.1124224 Shan, 2018, Autophagy and acetaminophen-induced hepatotoxicity, Arch Toxicol, 92, 2153, 10.1007/s00204-018-2237-5 Mammucari, 2007, FoxO3 controls autophagy in skeletal muscle in vivo, Cell Metab, 6, 458, 10.1016/j.cmet.2007.11.001 Pi, 2019, AKT inhibition-mediated dephosphorylation of TFE3 promotes overactive autophagy independent of MTORC1 in cadmium-exposed bone mesenchymal stem cells, Autophagy, 15, 565, 10.1080/15548627.2018.1531198 Liu, 2017, AMPK activation ameliorates d-GalN/LPS-induced acute liver failure by upregulating Foxo3A to induce autophagy, Exp Cell Res, 358, 335, 10.1016/j.yexcr.2017.07.008 Manley, 2015, Role of farnesoid X receptor and bile acids in alcoholic liver disease, Acta Pharm Sin B, 5, 158, 10.1016/j.apsb.2014.12.011 Zhong, 2015, Retinoic acid receptor α promotes autophagy to alleviate liver ischemia and reperfusion injury, World J Gastroenterol, 21, 12381, 10.3748/wjg.v21.i43.12381 Ni, 2013, Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity, Am J Pathol, 183, 1815, 10.1016/j.ajpath.2013.08.011 Tsapras, 2017, Caspase involvement in autophagy, Cell Death Differ, 24, 1369, 10.1038/cdd.2017.43 Fitzwalter, 2018, FOXO3 links autophagy to apoptosis, Autophagy, 14, 1467, 10.1080/15548627.2018.1475819 Sakata, 2020, The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events, Asia Pac J Clin Oncol, 16, e113, 10.1111/ajco.13103 Li, 2010, Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile, Drug Metab Dispos, 38, 1238, 10.1124/dmd.109.030361 Duckett, 2010, Metabolism considerations for kinase inhibitors in cancer treatment, Expert Opin Drug Metab Toxicol, 6, 1175, 10.1517/17425255.2010.506873 Tan, 2015, A kinase-independent role for EGF receptor in autophagy initiation, Cell, 160, 145, 10.1016/j.cell.2014.12.006 Chen, 2018, Mitochondrial pathway-mediated apoptosis is associated with erlotinib-induced cytotoxicity in hepatic cells, Oncol Lett, 15, 783